한글목차

세계의 바이러스 및 비바이러스 벡터 시장 규모는 2023년에 5억 5,185만 달러에 달했습니다.

시장은 2024-2030년 예측기간 동안 31.84%의 CAGR로 확대되어 2030년까지 35억 500만 달러에 달할 것으로 예측됩니다.

북미의 바이러스 및 비바이러스 벡터 시장 규모는 2023년에 2억 3,200만 달러에 달했습니다. 시장은에서 2024년부터 2030년 예측기간에 31%의 CAGR로 확대되어 2030년에는 14억 2,300만 달러에 달할 것으로 예측됩니다.

아시아태평양의 바이러스 및 비바이러스 벡터 시장 규모는 2023년에 1억 4,100만 달러에 달했습니다. 시장은 2024년부터 2030년 예측기간 동안 33.67%의 CAGR로 확대되어 2030년에는 9억 8,300만 달러에 달할 것으로 예측됩니다.

바이러스 및 비바이러스 벡터의 주요 세계 기업에는 Lonza, Thermo Fisher Scientific, VectorBuilder, GenScript Biotech, Gene Chem, Revvity 등이 있습니다. 2023년에는 세계 상위 5개 벤더가 매출의 약 62.03%를 차지하고 있습니다.

세계의 바이러스 및 비바이러스 벡터 시장에 대해 조사했으며, 시장 개요와 함께 유형별, 용도별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 보고서 개요

• 조사 범위
• 유형별 시장 분석
• 용도별 시장
• 가정과 제한
• 조사 목적
• 대상 연도

제2장 세계의 성장 동향

• 세계의 바이러스 및 비바이러스 벡터 시장 전망(2019-2030년)
• 세계의 바이러스 및 비바이러스 벡터 성장 동향, 지역별
• 바이러스 및 비바이러스 벡터 시장 역학

제3장 주요 진출 기업에 의한 경쟁 구도

제4장 바이러스 및 비바이러스 벡터 내역 데이터, 유형별

• 세계의 바이러스 및 비바이러스 벡터 시장 규모 실적, 유형별(2019-2024년)
• 세계의 바이러스 및 비바이러스 벡터 시장 규모 예측, 유형별(2025-2030년)

제5장 바이러스 및 비바이러스 벡터 내역 데이터, 용도별

• 세계의 바이러스 및 비바이러스 벡터 시장 규모 실적, 용도별(2019-2024년)
• 세계의 바이러스 및 비바이러스 벡터 시장 규모 예측, 용도별(2025-2030년)

제6장 북미

제7장 유럽

제8장 아시아태평양

제9장 남미

제10장 중동 및 아프리카

제11장 주요인 기업 로파일

• Thermo Fisher Scientific
• Lonza
• Azenta Life Sciences
• Revvity
• VectorBuilder
• Takara Bio
• GenScript Biotech
• Gene Chem
• Geno Meditech
• PackGene Biotech
• VIROVEK
• OriGen
• Vector BioLabs

제12장 애널리스트의 견해/결론

제13장 부록

영문목차

The global Viral and Non-viral Vector market was valued at US$ 551.85 million in 2023 and is anticipated to reach US$ 3505 million by 2030, witnessing a CAGR of 31.84% during the forecast period 2024-2030.

North American market for Viral and Non-viral Vector is estimated to increase from $ 232 million in 2023 to reach $ 1423million by 2030, at a CAGR of 31% during the forecast period of 2024 through 2030.

Asia-Pacific market for Viral and Non-viral Vector is estimated to increase from $ 141 million in 2023 to reach $ 983 million by 2030, at a CAGR of 33.67% during the forecast period of 2024 through 2030.

The major global companies of Viral and Non-viral Vector include Lonza, Thermo Fisher Scientific, VectorBuilder, GenScript Biotech, Gene Chem, Revvity, etc. In 2023, the world's top five vendors accounted for approximately 62.03 % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Viral and Non-viral Vector, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral and Non-viral Vector.

The Viral and Non-viral Vector market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral and Non-viral Vector market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Viral and Non-viral Vector companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

• Thermo Fisher Scientific
• Lonza
• Azenta Life Sciences
• Revvity
• VectorBuilder
• Takara Bio
• GenScript Biotech
• Gene Chem
• Geno Meditech
• PackGene Biotech
• VIROVEK
• OriGen
• Vector BioLabs

Segment by Type

• AAV
• Lentiviruses
• Retroviruses
• Adenoviruses
• DNA Plasmids
• Others

Segment by Application

• Pharmaceutical and Biopharmaceutical Companies
• Academics and Research Institutes
• Others

By Region

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Rest of Europe
• South America
• Brazil
• Rest of South America
• Middle East & Africa
• Middle East
• Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Viral and Non-viral Vector company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Viral and Non-viral Vector Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
  • 1.2.2 AAV
  • 1.2.3 Lentiviruses
  • 1.2.4 Retroviruses
  • 1.2.5 Adenoviruses
  • 1.2.6 DNA Plasmids
• 1.3 Market by Application
  • 1.3.1 Global Viral and Non-viral Vector Market Growth by Application: 2019 VS 2023 VS 2030
  • 1.3.2 Pharmaceutical and Biopharmaceutical Companies
  • 1.3.3 Academics and Research Institutes
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Viral and Non-viral Vector Market Perspective (2019-2030)
• 2.2 Global Viral and Non-viral Vector Growth Trends by Region
  • 2.2.1 Global Viral and Non-viral Vector Market Size by Region: 2019 VS 2023 VS 2030
  • 2.2.2 Viral and Non-viral Vector Historic Market Size by Region (2019-2024)
  • 2.2.3 Viral and Non-viral Vector Forecasted Market Size by Region (2025-2030)
• 2.3 Viral and Non-viral Vector Market Dynamics
  • 2.3.1 Viral and Non-viral Vector Industry Trends
  • 2.3.2 Viral and Non-viral Vector Market Drivers
  • 2.3.3 Viral and Non-viral Vector Market Challenges
  • 2.3.4 Viral and Non-viral Vector Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Viral and Non-viral Vector Players by Revenue
  • 3.1.1 Global Top Viral and Non-viral Vector Players by Revenue (2019-2024)
  • 3.1.2 Global Viral and Non-viral Vector Revenue Market Share by Players (2019-2024)
• 3.2 Global Viral and Non-viral Vector Market by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Global Key Players Ranking by Viral and Non-viral Vector Revenue
• 3.4 Global Viral and Non-viral Vector Market Concentration Ratio
  • 3.4.1 Global Viral and Non-viral Vector Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Viral and Non-viral Vector Revenue in 2023
• 3.5 Global Key Players of Viral and Non-viral Vector Head office and Area Served
• 3.6 Global Key Players of Viral and Non-viral Vector, Product
• 3.7 Global Key Players of Viral and Non-viral Vector, Founded Date
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Viral and Non-viral Vector Breakdown Data by Type

• 4.1 Global Viral and Non-viral Vector Historic Market Size by Type (2019-2024)
• 4.2 Global Viral and Non-viral Vector Forecasted Market Size by Type (2025-2030)

5 Viral and Non-viral Vector Breakdown Data by Application

• 5.1 Global Viral and Non-viral Vector Historic Market Size by Application (2019-2024)
• 5.2 Global Viral and Non-viral Vector Forecasted Market Size by Application (2025-2030)

6 North America

• 6.1 North America Viral and Non-viral Vector Market Size (2019-2030)
• 6.2 North America Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
• 6.3 North America Viral and Non-viral Vector Market Size by Country (2019-2024)
• 6.4 North America Viral and Non-viral Vector Market Size by Country (2025-2030)
• 6.5 United States
• 6.6 Canada
• 6.7 Mexico

7 Europe

• 7.1 Europe Viral and Non-viral Vector Market Size (2019-2030)
• 7.2 Europe Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
• 7.3 Europe Viral and Non-viral Vector Market Size by Country (2019-2024)
• 7.4 Europe Viral and Non-viral Vector Market Size by Country (2025-2030)
• 7.5 Germany
• 7.6 France
• 7.7 U.K.
• 7.8 Italy
• 7.9 Russia
• 7.10 Spain

8 Asia-Pacific

• 8.1 Asia-Pacific Viral and Non-viral Vector Market Size (2019-2030)
• 8.2 Asia-Pacific Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
• 8.3 Asia-Pacific Viral and Non-viral Vector Market Size by Region (2019-2024)
• 8.4 Asia-Pacific Viral and Non-viral Vector Market Size by Region (2025-2030)
• 8.5 China
• 8.6 Japan
• 8.7 South Korea
• 8.8 Southeast Asia
• 8.9 India
• 8.10 Australia

9 South America

• 9.1 South America Viral and Non-viral Vector Market Size (2019-2030)
• 9.2 South America Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
• 9.3 South America Viral and Non-viral Vector Market Size by Country (2019-2024)
• 9.4 South America Viral and Non-viral Vector Market Size by Country (2025-2030)
• 9.5 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Viral and Non-viral Vector Market Size (2019-2030)
• 10.2 Middle East & Africa Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030
• 10.3 Middle East & Africa Viral and Non-viral Vector Market Size by Country (2019-2024)
• 10.4 Middle East & Africa Viral and Non-viral Vector Market Size by Country (2025-2030)
• 10.5 Middle East
• 10.6 Africa

11 Key Players Profiles

• 11.1 Thermo Fisher Scientific
  • 11.1.1 Thermo Fisher Scientific Company Details
  • 11.1.2 Thermo Fisher Scientific Business Overview
  • 11.1.3 Thermo Fisher Scientific Viral and Non-viral Vector Introduction
  • 11.1.4 Thermo Fisher Scientific Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.1.5 Thermo Fisher Scientific Recent Development
• 11.2 Lonza
  • 11.2.1 Lonza Company Details
  • 11.2.2 Lonza Business Overview
  • 11.2.3 Lonza Viral and Non-viral Vector Introduction
  • 11.2.4 Lonza Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.2.5 Lonza Recent Development
• 11.3 Azenta Life Sciences
  • 11.3.1 Azenta Life Sciences Company Details
  • 11.3.2 Azenta Life Sciences Business Overview
  • 11.3.3 Azenta Life Sciences Viral and Non-viral Vector Introduction
  • 11.3.4 Azenta Life Sciences Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.3.5 Azenta Life Sciences Recent Development
• 11.4 Revvity
  • 11.4.1 Revvity Company Details
  • 11.4.2 Revvity Business Overview
  • 11.4.3 Revvity Viral and Non-viral Vector Introduction
  • 11.4.4 Revvity Revenue in Viral and Non-viral Vector Business (2019-2024)
• 11.5 VectorBuilder
  • 11.5.1 VectorBuilder Company Details
  • 11.5.2 VectorBuilder Business Overview
  • 11.5.3 VectorBuilder Viral and Non-viral Vector Introduction
  • 11.5.4 VectorBuilder Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.5.5 VectorBuilder Recent Development
• 11.6 Takara Bio
  • 11.6.1 Takara Bio Company Details
  • 11.6.2 Takara Bio Business Overview
  • 11.6.3 Takara Bio Viral and Non-viral Vector Introduction
  • 11.6.4 Takara Bio Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.6.5 Takara Bio Recent Development
• 11.7 GenScript Biotech
  • 11.7.1 GenScript Biotech Company Details
  • 11.7.2 GenScript Biotech Business Overview
  • 11.7.3 GenScript Biotech Viral and Non-viral Vector Introduction
  • 11.7.4 GenScript Biotech Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.7.5 GenScript Biotech Recent Development
• 11.8 Gene Chem
  • 11.8.1 Gene Chem Company Details
  • 11.8.2 Gene Chem Business Overview
  • 11.8.3 Gene Chem Viral and Non-viral Vector Introduction
  • 11.8.4 Gene Chem Revenue in Viral and Non-viral Vector Business (2019-2024)
• 11.9 Geno Meditech
  • 11.9.1 Geno Meditech Company Details
  • 11.9.2 Geno Meditech Business Overview
  • 11.9.3 Geno Meditech Viral and Non-viral Vector Introduction
  • 11.9.4 Geno Meditech Revenue in Viral and Non-viral Vector Business (2019-2024)
• 11.10 PackGene Biotech
  • 11.10.1 PackGene Biotech Company Details
  • 11.10.2 PackGene Biotech Business Overview
  • 11.10.3 PackGene Biotech Viral and Non-viral Vector Introduction
  • 11.10.4 PackGene Biotech Revenue in Viral and Non-viral Vector Business (2019-2024)
• 11.11 VIROVEK
  • 11.11.1 VIROVEK Company Details
  • 11.11.2 VIROVEK Business Overview
  • 11.11.3 VIROVEK Viral and Non-viral Vector Introduction
  • 11.11.4 VIROVEK Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.11.5 VIROVEK Recent Development
• 11.12 OriGen
  • 11.12.1 OriGen Company Details
  • 11.12.2 OriGen Business Overview
  • 11.12.3 OriGen Viral and Non-viral Vector Introduction
  • 11.12.4 OriGen Revenue in Viral and Non-viral Vector Business (2019-2024)
• 11.13 Vector BioLabs
  • 11.13.1 Vector BioLabs Company Details
  • 11.13.2 Vector BioLabs Business Overview
  • 11.13.3 Vector BioLabs Viral and Non-viral Vector Introduction
  • 11.13.4 Vector BioLabs Revenue in Viral and Non-viral Vector Business (2019-2024)
  • 11.13.5 Vector BioLabs Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details
• 13.3 Disclaimer 119